Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
National Institute for Health and Clinical Excellence
Record ID 32006000195
English
Authors' objectives:
The aim of this report is to assess the use of adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Authors' recommendations:
1 Guidance
This guidance does not apply to people with chronic hepatitis B known to be co-infected with hepatitis C, hepatitis D or HIV.
1.1 Peginterferon alfa-2a is recommended as an option for the initial treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative), within its licensed indications.
1.2 Adefovir dipivoxil is recommended as an option for the treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative) within its licensed indications if: - treatment with interferon alfa or peginterferon alfa-2a has been unsuccessful, or - a relapse occurs after successful initial treatment, or - treatment with interferon alfa or peginterferon alfa-2a is poorly tolerated or contraindicated.
1.3 Adefovir dipivoxil should not normally be given before treatment with lamivudine. It may be used either alone or in combination with lamivudine when: - treatment with lamivudine has resulted in viral resistance, or - lamivudine resistance is likely to occur rapidly (for example, in the presence of highly replicative hepatitis B disease), and development of lamivudine resistance is likely to have an adverse outcome (for example, if a flare of the infection is likely to precipitate decompensated liver disease).
1.4 Drug treatment with peginterferon alfa-2a or adefovir dipivoxil should be initiated only by an appropriately qualified healthcare professional with expertise in the management of viral hepatitis. Continuation of therapy under shared-care arrangements with a general practitioner is appropriate.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/page.aspx?o=293296
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Adenine
- Hepatitis B, Chronic
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.